Cargando…
In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia, excessive acetylcholinesterase (AChE) activity, formation of neurotoxic amyloid plaque, and tau protein aggregation. Based on literature survey, we have shortlisted three important target proteins (AChE, COX2, a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085546/ https://www.ncbi.nlm.nih.gov/pubmed/30123124 http://dx.doi.org/10.3389/fphar.2018.00730 |
_version_ | 1783346352596451328 |
---|---|
author | Rasool, Mahmood Malik, Arif Waquar, Sulayman Tul-Ain, Qura Jafar, Tassadaq H. Rasool, Rabia Kalsoom, Aasia Ghafoor, Muhammad A. Sehgal, Sheikh A. Gauthaman, Kalamegam Naseer, Muhammad I. Al-Qahtani, Mohammed H. Pushparaj, Peter N. |
author_facet | Rasool, Mahmood Malik, Arif Waquar, Sulayman Tul-Ain, Qura Jafar, Tassadaq H. Rasool, Rabia Kalsoom, Aasia Ghafoor, Muhammad A. Sehgal, Sheikh A. Gauthaman, Kalamegam Naseer, Muhammad I. Al-Qahtani, Mohammed H. Pushparaj, Peter N. |
author_sort | Rasool, Mahmood |
collection | PubMed |
description | Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia, excessive acetylcholinesterase (AChE) activity, formation of neurotoxic amyloid plaque, and tau protein aggregation. Based on literature survey, we have shortlisted three important target proteins (AChE, COX2, and MMP8) implicated in the pathogenesis of AD and 20 different phytocompounds for molecular docking experiments with these three target proteins. The 3D-structures of AChE, COX2, and MMP8 were predicted by homology modeling by MODELLER and the threading approach by using ITASSER. Structure evaluations were performed using ERRAT, Verify3D, and Rampage softwares. The results based on molecular docking studies confirmed that there were strong interactions of these phytocompounds with AChE, COX2, and MMP8. The top three compounds namely Albiziasaponin-A, Iso-Orientin, and Salvadorin showed least binding energy and highest binding affinity among all the scrutinized compounds. Post-docking analyses showed the following free energy change for Albiziasaponin-A, Salvadorin, and Iso-Orientin (−9.8 to −15.0 kcal/mol) as compared to FDA approved drugs (donepezil, galantamine, and rivastigmine) for AD (−6.6 to −8.2 Kcal/mol) and interact with similar amino acid residues (Pro-266, Asp-344, Trp-563, Pro-568, Tyr-103, Tyr-155, Trp-317, and Tyr-372) with the target proteins. Furthermore, we have investigated the antioxidant and anticholinesterase activity of these top three phytochemicals namely, Albiziasaponin-A, Iso-Orientin, and Salvadorin in colchicine induced rat model of AD. Sprague Dawley (SD) rat model of AD were developed using bilateral intracerebroventricular (ICV) injection of colchicine (15 μg/rat). After the induction of AD, the rats were subjected to treatment with phytochemicals individually or in combination for 3 weeks. The serum samples were further analyzed for biomarkers such as 8-hydroxydeoxyguanosine (8-OHdG), 4-hydroxynonenal (4-HNE), tumor necrosis factor-alpha (TNF-α), cyclooxygenase-2 (COX-2), matrix metalloproteinase-8 (MMP-8), isoprostanes-2 alpha (isoP-2α), and acetylcholine esterase (AChE) using conventional Enzyme Linked Immunosorbent Assay (ELISA) method. Additionally, the status of lipid peroxidation was estimated calorimetrically by measuring thiobarbituric acid reactive substances (TBARS). Here, we observed a statistically significant reduction (P < 0.05) in the oxidative stress and inflammatory markers in the treatment groups receiving mono and combinational therapies using Albiziasaponin-A, Iso-Orientin, and Salvadorin as compared to colchicine alone group. Besides, the ADMET profiles of these phytocompounds were very promising and, hence, these potential neuroprotective agents may further be taken for preclinical studies either as mono or combinational therapy for AD. |
format | Online Article Text |
id | pubmed-6085546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60855462018-08-17 In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease Rasool, Mahmood Malik, Arif Waquar, Sulayman Tul-Ain, Qura Jafar, Tassadaq H. Rasool, Rabia Kalsoom, Aasia Ghafoor, Muhammad A. Sehgal, Sheikh A. Gauthaman, Kalamegam Naseer, Muhammad I. Al-Qahtani, Mohammed H. Pushparaj, Peter N. Front Pharmacol Pharmacology Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia, excessive acetylcholinesterase (AChE) activity, formation of neurotoxic amyloid plaque, and tau protein aggregation. Based on literature survey, we have shortlisted three important target proteins (AChE, COX2, and MMP8) implicated in the pathogenesis of AD and 20 different phytocompounds for molecular docking experiments with these three target proteins. The 3D-structures of AChE, COX2, and MMP8 were predicted by homology modeling by MODELLER and the threading approach by using ITASSER. Structure evaluations were performed using ERRAT, Verify3D, and Rampage softwares. The results based on molecular docking studies confirmed that there were strong interactions of these phytocompounds with AChE, COX2, and MMP8. The top three compounds namely Albiziasaponin-A, Iso-Orientin, and Salvadorin showed least binding energy and highest binding affinity among all the scrutinized compounds. Post-docking analyses showed the following free energy change for Albiziasaponin-A, Salvadorin, and Iso-Orientin (−9.8 to −15.0 kcal/mol) as compared to FDA approved drugs (donepezil, galantamine, and rivastigmine) for AD (−6.6 to −8.2 Kcal/mol) and interact with similar amino acid residues (Pro-266, Asp-344, Trp-563, Pro-568, Tyr-103, Tyr-155, Trp-317, and Tyr-372) with the target proteins. Furthermore, we have investigated the antioxidant and anticholinesterase activity of these top three phytochemicals namely, Albiziasaponin-A, Iso-Orientin, and Salvadorin in colchicine induced rat model of AD. Sprague Dawley (SD) rat model of AD were developed using bilateral intracerebroventricular (ICV) injection of colchicine (15 μg/rat). After the induction of AD, the rats were subjected to treatment with phytochemicals individually or in combination for 3 weeks. The serum samples were further analyzed for biomarkers such as 8-hydroxydeoxyguanosine (8-OHdG), 4-hydroxynonenal (4-HNE), tumor necrosis factor-alpha (TNF-α), cyclooxygenase-2 (COX-2), matrix metalloproteinase-8 (MMP-8), isoprostanes-2 alpha (isoP-2α), and acetylcholine esterase (AChE) using conventional Enzyme Linked Immunosorbent Assay (ELISA) method. Additionally, the status of lipid peroxidation was estimated calorimetrically by measuring thiobarbituric acid reactive substances (TBARS). Here, we observed a statistically significant reduction (P < 0.05) in the oxidative stress and inflammatory markers in the treatment groups receiving mono and combinational therapies using Albiziasaponin-A, Iso-Orientin, and Salvadorin as compared to colchicine alone group. Besides, the ADMET profiles of these phytocompounds were very promising and, hence, these potential neuroprotective agents may further be taken for preclinical studies either as mono or combinational therapy for AD. Frontiers Media S.A. 2018-08-02 /pmc/articles/PMC6085546/ /pubmed/30123124 http://dx.doi.org/10.3389/fphar.2018.00730 Text en Copyright © 2018 Rasool, Malik, Waquar, Tul-Ain, Jafar, Rasool, Kalsoom, Ghafoor, Sehgal, Gauthaman, Naseer, Al-Qahtani and Pushparaj. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Rasool, Mahmood Malik, Arif Waquar, Sulayman Tul-Ain, Qura Jafar, Tassadaq H. Rasool, Rabia Kalsoom, Aasia Ghafoor, Muhammad A. Sehgal, Sheikh A. Gauthaman, Kalamegam Naseer, Muhammad I. Al-Qahtani, Mohammed H. Pushparaj, Peter N. In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease |
title | In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease |
title_full | In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease |
title_fullStr | In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease |
title_full_unstemmed | In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease |
title_short | In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease |
title_sort | in-silico characterization and in-vivo validation of albiziasaponin-a, iso-orientin, and salvadorin using a rat model of alzheimer's disease |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085546/ https://www.ncbi.nlm.nih.gov/pubmed/30123124 http://dx.doi.org/10.3389/fphar.2018.00730 |
work_keys_str_mv | AT rasoolmahmood insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT malikarif insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT waquarsulayman insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT tulainqura insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT jafartassadaqh insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT rasoolrabia insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT kalsoomaasia insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT ghafoormuhammada insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT sehgalsheikha insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT gauthamankalamegam insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT naseermuhammadi insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT alqahtanimohammedh insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease AT pushparajpetern insilicocharacterizationandinvivovalidationofalbiziasaponinaisoorientinandsalvadorinusingaratmodelofalzheimersdisease |